Midgard Science

MindWalk

Victoria, BC, Canada mindwalkai.com

From their website, Nov 2026

Work here? Claim this listing

About

MindWalk is an antibody discovery company serving pharma, biotech, and academic partners. It provides end-to-end discovery, development, optimization, and protein production services for therapeutic, diagnostic, and research biologics from sites in the USA, Canada, and Belgium.

Services

  • Antibody discovery, development, and optimization

    End-to-end antibody discovery from target analysis through optimized lead selection using wet-lab workflows and AI-enabled analysis.

  • Therapeutic antibody discovery

    Function-first discovery and development of therapeutic antibodies selected for function, not just binding.

  • Anti-drug and anti-idiotype antibody discovery

    Discovery of anti-drug and anti-idiotypic antibodies with reproducible data packages and validated assays.

  • Diagnostic antibody discovery

    Discovery of diagnostic antibodies designed for high affinity, sensitivity, specificity, reproducibility, and scalable performance.

  • Research antibody discovery

    Discovery of antibodies for research and analytical applications, including custom solutions for challenging targets.

  • Protein engineering, expression, and production

    Design, expression, and production of recombinant proteins and antibody formats, from sequence to purified protein.

  • LensAI analysis

    AI analysis for epitope mapping, paratyping, developability, immunogenicity, and candidate evaluation.

  • MindWalk Collaborative

    Events, webisodes, and collaborative forums for biologics R&D.

  • Antibody discovery programs

    End-to-end antibody discovery, development, and optimization customized to a target.

  • B cell Select® discovery

    Functional antibody discovery platform with >98% discovery success rate stated by the company.

  • B cell Llama™ VHH discovery

    Direct B cell VHH discovery platform for bispecific, multispecific, and other therapeutic formats.

  • Hybridoma discovery

    Antibody discovery using hybridoma-based campaigns.

  • Yeast display discovery

    Antibody discovery using yeast display.

  • Therapeutic antibodies

    Discovery support for therapeutic antibody programs.

  • Anti-drug & anti-idiotype antibodies

    Discovery and development support for anti-drug and anti-idiotype antibodies.

  • Diagnostic antibodies

    Discovery and development support for diagnostic antibodies.

  • Protein engineering & production

    Protein engineering and production services.

  • ReefIQ™

    Biological context layer that connects discovery data and adds biological meaning for AI drug discovery.

  • LensAI™

    AI analysis platform used in programs for epitope mapping, paratyping, developability, immunogenicity, and candidate evaluation.

Turnaround
From sequence to purified recombinant antibody: 3 weeks · 8-10 weeks for new custom proteins · B cell discovery: From immunization to delivery <12 weeks

Capabilities

Assays and studies
Antibodies · Hybridoma · Immunogenicity · Bispecifics · Epitope mapping · Paratyping · Developability assessment · Immunogenicity screening · Candidate evaluation · Binding affinity optimization · Target specificity assessment · Selectivity assessment
5 moreWestern blot · IHC · Flow cytometry · Developability · Anti-drug-antibody risk prediction
Scale and capacity
100 µg–1 mg · 10–50 mg · Gram-scale production · Over 20 publicly disclosed client antibodies have entered the clinic · Ten in the clinic today · Four first in class · 3,000 times
Therapeutic areas
Oncology · Infectious disease · Neurodegeneration · Metabolic disease · Rare disease · Inflammation · Drug discovery

Instruments and platforms

  • X-ray crystallography

Modalities and species

Modalities
Antibody · Bispecific · Peptide · Recombinant protein · Vaccine
Species and models
Rabbit · Chicken · Camelid · Mouse · HEK293 · CHO · E. coli · Camelid immune repertoire

Industries served

  • Biotech
  • Pharma
  • Academic research
  • Biologics
  • Drug discovery
  • Diagnostics

Company

Type
CRDMO
Founded
2019
Quality
>98% discovery success rate (B cell Select® discovery success rate) · 100% success rate (anti-idiotypic antibody discovery to date) · #1 antibody discovery and development co (Roots Analysis (2022)) · LensAI won the 2024 InterSystems Impact (outperforming more than 1,000 global biotherapeutic research projects) · Patented HYFT® technology (EP3881326)

Locations

Address
823 Congress Ave Suite 300 Austin, TX 78701, USA
Sites
Austin, USA · Fargo, USA · Victoria, Canada · Diepenbeek, Belgium
Serves
USA, Canada, Europe, global

Contacts

Public records

Wikidata
Q30282844 source

Similar labs

Work here? Claim this listing